Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aptevo Therapeutics Inc. is a publicly traded clinical-stage biotechnology company focused on the development of novel immuno-oncology therapies for the treatment of cancer. The company operates within the biotechnology and oncology therapeutics industries, with an emphasis on engineered antibody-based treatments designed to engage the immune system to target malignant cells. Aptevo’s core scientific approach centers on its proprietary ADAPTIR® and ADAPTIR-FLEX® antibody technology platforms, which are used to create bispecific and multispecific therapeutic candidates.
Aptevo’s primary revenue drivers are currently research collaborations, licensing arrangements, and potential milestone payments, as the company does not yet have an approved commercial product. Its lead clinical programs are focused on hematologic malignancies, particularly acute myeloid leukemia (AML). The company serves oncology clinicians, healthcare systems, and patients through clinical trial programs rather than direct commercial sales. Aptevo was formed in 2016 through a spin-out from Emergent BioSolutions, Inc., inheriting antibody engineering assets and refocusing the business on oncology drug development.
Business Operations
Aptevo operates as a single-reportable-segment biotechnology company, generating revenue primarily from collaboration agreements and government or partner-supported research funding. Its development pipeline is built around internally developed immunotherapy candidates, including mipletamig (formerly APVO436), a bispecific antibody targeting CD123 and CD3 for the treatment of AML and myelodysplastic syndromes, and ALG.APV-527, a bispecific antibody targeting 4-1BB and a tumor-associated antigen for solid tumors. The company’s operations are heavily weighted toward research and development activities.
The company conducts its clinical trials through a network of domestic and international research institutions and clinical sites, while maintaining internal control over its antibody engineering technologies. Aptevo has entered into strategic partnerships and licensing agreements with pharmaceutical companies for regional development rights to certain candidates. Some historical and ongoing collaborations have involved international partners for development and commercialization outside the United States; where public disclosures vary on scope or status, data is inconclusive based on available public sources.
Strategic Position & Investments
Aptevo’s strategic direction is focused on advancing its proprietary immuno-oncology pipeline through early- and mid-stage clinical development, while selectively pursuing partnerships to extend its financial runway and global reach. Growth initiatives center on expanding the clinical data set for mipletamig and progressing next-generation ADAPTIR-based candidates that aim to improve efficacy while reducing cytokine-related toxicity associated with earlier bispecific antibodies.
The company has historically relied on asset-level licensing and collaboration agreements rather than large-scale acquisitions. Aptevo does not operate a diversified investment portfolio; instead, it allocates capital primarily toward internal R&D and clinical trials. Emerging areas of focus include conditional T-cell activation, tumor-targeted immune co-stimulation, and modular antibody engineering, which the company believes may offer competitive differentiation within the crowded immunotherapy landscape.
Geographic Footprint
Aptevo is headquartered in Seattle, Washington, and its core corporate, research, and administrative functions are based in the United States. The company’s operational footprint is relatively lean, consistent with a clinical-stage biotechnology firm, with no large-scale manufacturing facilities disclosed in public filings.
Internationally, Aptevo maintains a presence through clinical trial sites and development partnerships in Europe and Asia, supporting patient enrollment and regional development strategies for select pipeline assets. While the company does not report significant foreign revenue, its international collaborations provide strategic access to non-U.S. markets and regulatory pathways.
Leadership & Governance
Aptevo is led by an executive team with experience in biotechnology, oncology drug development, and public company governance. The leadership’s stated strategic vision emphasizes disciplined capital allocation, scientific differentiation through proprietary platforms, and partnership-driven value creation while advancing high-need oncology indications.
Key executives include:
- Marvin J. White – President and Chief Executive Officer
- David S. Dyer – Chief Financial Officer
- Scott Stromatt – Chief Medical Officer
- Marianne De Backer – Chair of the Board of Directors
The board of directors provides oversight on strategy, risk management, and corporate governance, with committees aligned to audit, compensation, and scientific oversight functions typical of U.S.-listed biotechnology companies.